Preclinical Pharmacokinetic/Pharmacodynamic Modeling and Simulation in the Pharmaceutical Industry: An IQ Consortium Survey Examining the Current Landscape

AAPS Journal

Volumn 17, Issue 2, 2015, Pages 462-473

  Schuck, Edgar ^a   Bohnert, Tonika ^b   Chakravarty, Arijit ^c   Damian Iordache, Valeriu ^d   Gibson, Christopher ^e   Hsu, Cheng Pang ^f   Heimbach, Tycho ^g   Krishnatry, Anu Shilpa ^d   Liederer, Bianca M ^h   Lin, Jing ⁱ   Maurer, Tristan ^j   Mettetal, Jerome T ^k   Mudra, Daniel R ^l   Nijsen, Marjoleen JMA ^m   Raybon, Joseph ⁿ   Schroeder, Patricia ^o   Schuck, Virna ^k,r   Suryawanshi, Satyendra ⁿ   Su, Yaming ^p   Trapa, Patrick ^j   Tsai, Alice ^q   Vakilynejad, Majid ^c   Wang, Shining ^p   Wong, Harvey ^h   more..

^a EISAI INC   (United States)

^b BIOGEN   (United States)

^c Takeda ^*  (United States)

^d GLAXOSMITHKLINE   (United States)

^e MERCK RESEARCH LABORATORIES   (United States)

^f AMGEN INC   (United States)

^g NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH   (United States)

^h GENENTECH INC   (United States)

ⁱ DAINIPPON SUMITOMO PHARMA CO LTD   (Japan)

^j PFIZER INC   (United States)

^k ASTRAZENECA   (United Kingdom)

^l ELI LILLY AND COMPANY   (United States)

^m ABBVIE INC   (United States)

ⁿ BRISTOL MYERS SQUIBB   (United States)

^o EMD Serono   (United States)

^p SANOFI   (France)

^q VERTEX PHARMACEUTICALS   (United States)

^r NOVARTIS PHARMA AG   (Switzerland)

more..

Author keywords

pharmaceutical industry; preclinical pharmacokinetic pharmacodynamic modeling; simulation

Indexed keywords

BIOLOGICAL MODEL; COMPUTER SIMULATION; DOSE RESPONSE; DRUG DESIGN; DRUG DEVELOPMENT; DRUG INDUSTRY; HUMAN; INFORMATION PROCESSING; PRECLINICAL STUDY; PROCEDURES; STATISTICS AND NUMERICAL DATA;

COMPUTER SIMULATION; DATA COLLECTION; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG DESIGN; DRUG DISCOVERY; DRUG EVALUATION, PRECLINICAL; DRUG INDUSTRY; HUMANS; MODELS, BIOLOGICAL;

EID: 84939957736     PISSN: None     EISSN: 15507416     Source Type: Journal    
DOI: 10.1208/s12248-014-9716-2     Document Type: Article

References (18)

1. Arrowsmith J. Trial watch: phase II failures: 2008–2010. Nat Rev Drug Discov. 2011;10:328–9. doi:10.1038/nrd3439.
2. Arrowsmith J. Trial watch: phase III and submission failures: 2007–2010. Nat Rev Drug Discov. 2011;10:87. doi:10.1038/nrd3375.
3. Chang C, Byon W, Lu Y, Jacobsen LK, Badura LL, Sawant-Basak A, et al. Quantitative PK-PD model-based translational pharmacology of a novel kappa opioid receptor antagonist between rats and humans. AAPS J. 2011;13:565–75. doi:10.1208/s12248-011-9296-3.
4. Heimbach T, Gollen R, He H. Practical anticipation of human efficacious doses and pharmacokinetics using preclinical in vitro and in vivo data. In: Wang J, Urban L, editors. Predictive ADMET: Integrated approaches in drug discovery and development. Wiley Inc.; 2014. p. 319–352.
5. Jones RD, Jones HM, Rowland M, Gibson CR, Yates JW, Chien JY, et al. PhRMA CPCDC initiative on predictive models of human pharmacokinetics, part 2: comparative assessment of prediction methods of human volume of distribution. J Pharm Sci. 2011;100:4074–89.
6. Kola I, Landis J. Can the pharmaceutical industry reduce attrition rates? Nat Rev Drug Discov. 2004;3:711–5.
7. Liu L, Di Paolo J, Barbosa J, Rong H, Reif K, Wong H. Anti-arthritis effect of a novel Bruton’s tyrosine kinase inhibitor in Rat collagen-induced arthritis and mechanism-based pharmacokinetic/pharmacodynamic modeling: relationships between inhibition of BTK phosphorylation and efficacy. J Pharmacol Exp Ther. 2011;338:154–63. doi:10.1124/jpet.111.181545.
8. Maurer TS, Ghosh A, Haddish-Berhane N, Sawant-Basak A, Boustany-Kari CM, She L, et al. Pharmacodynamic model of sodium-glucose transporter 2 (SGLT2) inhibition: implications for quantitative translational pharmacology. AAPS J. 2011;13:576–84. doi:10.1208/s12248-011-9297-2.
9. Obach RS, Baxter JG, Liston TE, Silber BM, Jones BC, MacIntyre F, et al. The prediction of human pharmacokinetic parameters from preclinical and in vitro metabolism data. J Pharmacol Exp Ther. 1997;283:46–58.
10. Ring BJ, Chien JY, Adkison KK, Jones HM, Rowland M, Jones RD, et al. PhRMA CPCDC initiative on predictive models of human pharmacokinetics, part 3: comparative assessement of prediction methods of human clearance. J Pharm Sci. 2011;100:4090–110.
11. Salphati L, Wong H, Belvin M, Edgar KA, Prior WW, Sampath D, et al. Pharmacokinetic-pharmacodynamic modeling of tumor growth inhibition and biomarker modulation by the novel PI3K inhibitor 2-(1H-indazol-4-yl)-6-(4-methanesulfonyl-piperazin-1-ylmethyl)-4-morpholin-4-yl-thieno[3,2-d]pyrimidine (GDC-0941). Drug Metab Dispos. 2010;38:1436–42. doi:10.1124/dmd.110.032912.
12. Vlasakakis G, Comets E, Keunecke A, Gueorguieva I, Magni P, Terranova N, et al. White paper: landscape on technical and conceptual requirements and competence framework in drug/disease modeling and simulation. CPT Pharmacometrics Syst Pharmacol. 2013;2:e40. doi:10.1038/psp.2013.16.
13. Ward KW, Proksch JW, Levy MA, Smith BR. Development of an in vivo preclinical screen model to estimate absorption and bioavailability of xenobiotics. Drug Metab Dispos. 2001;29:82–8.
14. Wong H, Grossman SJ, Bai SA, Diamond S, Wright MR, Grace Jr JE, et al. The chimpanzee (Pan troglodytes) as a pharmacokinetic model for selection of drug candidates: model characterization and application. Drug Metab Dispos. 2004;32:1359–69.
15. Wong H, Choo EF, Alicke B, Ding X, La H, McNamara E, et al. Anti-tumor activity of targeted and cytotoxic agents in murine subcutaneous tumor models correlates with clinical response. Clin Cancer Res. 2012;18:3846–55. doi:10.1158/1078-0432.CCR-12-0738.
16. Wong H, Vernillet L, Peterson A, Ware JA, Lee L, Martini J-F, et al. Bridging the Gap between preclinical and clinical studies using PK-PD modeling: an analysis of GDC-0973, a MEK inhibitor. Clin Cancer Res. 2012;18:3090–9. doi:10.1158/1078-0432.CCR-12-0445.
17. Yamazaki S, Vicini P, Shen Z, Zou HY, Lee J, Li Q, et al. Pharmacokinetic/pharmacodynamic modeling of crizotinib for anaplastic lymphoma kinase inhibition and antitumor efficacy in human tumor xenograft mouse models. J Pharmacol Exp Ther. 2012;340:549–57.
18. Zager MG, Kozminski K, Pascual B, Ogilvie KM, Sun S. Preclinical PK/PD modeling and human efficacious dose projection for a glucokinase activator in the treatment of diabetes. J Pharmacokinet Pharmacodyn. 2014;41:127–39. doi:10.1007/s10928-014-9351-7.